Amneal Pharma's Q4 Earnings Fall Short Of Expectations, Sees FY22 Sales Growth Of 7%

Amneal Pharmaceuticals Inc AMRX reports Q4 revenue of $537 million, an increase of 5% Y/Y, marginally missing the consensus of $537.35 million.

  • The increase was driven by Generic product launches and growth in Specialty products Rytary and Unithroid, partially offset by price erosion.
  • Adjusted EPS was $0.18, below the consensus of $0.20, and better than $0.14 posted a year ago.
  • Adjusted EBITDA increased 18% to $126 million, reflecting higher adjusted gross profit driven by higher revenues, reduced material costs, and operating efficiencies, partially offset by higher expenses.
  • Related: Amneal's $83M Saol Acquisition Deal Expands Its Neurology Presence Into Spasticity.
  • The company also entered the U.S. biosimilar market with FDA approval for filgrastim-ayow, a biosimilar referencing Neupogen, marketed under the proprietary name Releuko.
  • Releuko is used to treat neutropenia (low neutrophils, a type of white blood cells that fight infection) commonly experienced by chemotherapy patients. 
  • Amneal expects to launch Releuko in Q3 of 2022.
  • Outlook: Amneal expects FY22 sales of $2.15 billion - $2.25 billion, compared to the consensus of $2.17 billion.
  • The company expects adjusted EPS of $0.80 - $0.85, below the consensus of $0.90.
  • It expects adjusted EBITDA of $540 million - $560 million, with operating cash flow of $225 million - $250 million.
  • Price Action: AMRX shares closed 2.25% higher at $4.54 during after-hours trading on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksGuidanceHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!